Experiment 1170052
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV INFUSION |
| Organism | Empty organism |
| Citation | DABICH,L: BULL,FE: BELTRAN,G: ATHENS,JW: COLTMAN JR,CA: WEICK,JK: VAN SLYCK,EJ: AMARE,M:. (1986). PHASE II EVALUATION OF ACLARUBICIN IN REFRACTORY ADULT ACUTE LEUKEMIA: A SOUTHWEST ONCOLOGY GROUP STUDY.. 70(8) |
| Amount utilized | |
| Compound isolated | |
| Disease | 20 PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA AND FOUR WITH ACUTE LYMPHOBLASTIC LEUKEMIA WERE TREATED IN THIS PHASE II STUDY. A DOSE OF 75 MG/SG.M.WAS GIVEN FOR 4 CONSECUTIVE DAYS EVERY 3 WEEKS. SEVEN PATIENTS RECEIVED MORE THAN 2 COURSES OF THERAPY. OF THE 20 PATIENTS WITH MYELOGENOUS LEUKEMIA THERE WERE 2 COMPLETE REMISSIONS, LASTING 10 AND 16 MONTHS AND 1 PARTIAL REMISSION LASTING 4.5 MONTHS. NONE OF THE PATIENTS WITH LYMPHOBLASTIC LUEKEMIA RESPONDED TO TREATMENT. MYELOSUPPRESSION WAS SEVERE AND INCLUDED THROMBOCYTOPENIA (ALL PATIENTS NEEDED PLATELET TRANSFUSIONS),LEUKOPENIA (ALL PATIENTS NEEDED IV ANTIBIOTICS TO COUNTERACT SEPSIS),AND ANEMIA. NAUSEA AND VOMITING (50%), DIARRHEA (33%) AND MUCOSITIS (50%) WERE ALSO SEEN. NO CARDIAC SYMPTOMS WERE NOTED DURING DRUG INFUSION, HOWEVER 3 LATE EVENTS OCCURED. ONE PATIENT HAD VENTRICULAR TACHYCARDIA AFTER 5 DAYS, AND ANOTHER HAD NONSPECIFIC ST-T WAVE ABNORMALITIES AFTER 2 WEEKS. A THIRD PATIENT HAD ATRIA FLUTTER-FIBRILLATION ASSOCIATED WITH CONGESTIVE HEART FAILURE. THE CONGESTIVE HEART FAILURE WAS ATTRIBUTED TO SEPSIS BY THE ATTENDING PHYSICIANS. |
| Dose amount | 300.0 MG |
| Number | 1 |
| Qualitative result | EQUIVOCAL |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |